17 March 2026 in V.F.Snegirev Archives of Obstetrics and Gynecology
Currently, the problem of overweight and obesity has acquired global significance due to the high prevalence of these conditions and the associated multisystem pathological conditions, including reproductive disorders in both men and women. Contemporary medicine strongly recommends weight reduction to prevent metabolic complications and obesity-related comorbidities. The most effective and fundamental approach remains lifestyle modification, including a hypocaloric diet and moderate physical activity. However, a proportion of patients demonstrate resistance to such changes, necessitating the use of pharmacological agents and, in some cases, surgical treatment. Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated high efficacy in reducing body weight and improving glycemic control in patients with obesity and type 2 diabetes mellitus. However, data on the effects of semaglutide on the female reproductive system remain limited, as long-term clinical observations and studies under extreme conditions have been predominantly conducted in animal models. Particular attention is given to the effects of the drug in women of reproductive age, including its impact during preconception, the first trimester of pregnancy, and lactation, when both inadvertent and intentional exposure may have unpredictable consequences for the fetus and infant. This study presents a systematic review of current evidence regarding the use of semaglutide in female patients with obesity and examines the associated risks and contraindications during specific physiological states such as pregnancy and lactation. The findings are of substantial importance for developong clinical guidelines and establishing safe therapeutic strategies, which are essential for preserving reproductive health and supporting demographic stability.
28 February 2026 in V.F.Snegirev Archives of Obstetrics and Gynecology
ЩАЩеткина Мария Андреевна
+1
BACKGROUND: Medical students, as future doctors, have a prominent role in shaping medical culture and public opinion. Creating educational programs, events, and campaigns to support families with children, as well as instilling a positive attitude towards multi-child parenting in medical students, can help to increase birth rates in the near future. AIM: The work aimed to analyze the reproductive potential of medical students, identify factors influencing birth rates, and assess the commitment to traditional family values among young people. METHODS: An anonymous online survey among Sechenov University students was conducted. Primary endpoint: to obtain the results of the online survey (completed online questionnaires). Secondary endpoints: to analyze the findings and perform a comparative analysis of the answers based on the year of study and sex. RESULTS: The survey was conducted between August and December 2024. A total of 1785 students responded, including 1441 (80.7%) females and 344 (19.3%) males. The majority of respondents do not plan to have children while attending the University, citing financial constraints, housing issues, and concerns about the impact on their careers and childbirth. One of the main reasons for delaying motherhood is the desire for self-fulfillment and a successful career. Many female respondents claim that they delay having children in order to pursue a career and provide for themselves financially. A college degree leads to a desire for a higher social status, and women who pursue college education have more options for effective self-fulfillment outside of motherhood. CONCLUSION: Sustainable population growth necessitates long-term efforts to improve welfare and strengthen families. One potential strategy is to encourage medical students to promote family values and support multi-child parenting. The majority of medical students surveyed prioritize a successful career over family planning, without considering the age-related decline in fertility.
10 April 2024 in V.F.Snegirev Archives of Obstetrics and Gynecology
This paper presents a review of the current literature on the possible relationship between menopausal hormone therapy and Alzheimer’s disease. Increasing life expectancy in modern society is steadily leading to health problems in older women. Approximately 46.8 million people worldwide currently have cognitive disorders, and 2/3 of them are women. At the age of ≥65 years, every sixth woman and every eleventh man experience a form of higher nervous system pathologies. Older people are most often diagnosed with Alzheimer’s disease. It is a neurodegenerative disease that leads to problems with memory and cognitive functions and is characterized by changes in behavior and social-adaptive position of a person in society. One theory states that dementia is caused by changes in the endocrine status during menopause, particularly a decrease in estrogen levels. Currently, hormonal drugs are being considered a way to reduce the risk of neurological disorders. The possibility of preventing dementia, particularly Alzheimer’s disease, has long been of interest to leading experts in this field. The prevention of these diseases and prolongation of active longevity are becoming more relevant than ever. The relationship between menopausal hormone therapy and the risk of Alzheimer’s disease is receiving increasing attention.